HJB - Your Trusted Biologics CDMO Partner
HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB
XKH001 was designed and developed by Kanova. Currently other anti IL-25 candidates are all in pre-clinical development phase. XKH001 is the first FDA approved Anti IL-25 mAb which has good tolerance and safety. HJB's experienced team carried out process development, GMP manufacturing, and IND related studies seamlessly to guarantee the success of BI-5.
“It is a great milestone for Kanova to have FDA’s approval on XKH001 entering clinical phase. XKH001 will provide effective treatment for the patients who are suffering from refractory or drug resistance inflammation and allergies. Kanova will accelerate XKH001’s clinical development to benefit the patients.” said Yaning Wang, CEO of Kanova.
“Congratulations to Kanova on receiving approval for XKH001 to enter clinical phase. It is our honor to support Kanova for XKH001’s development, manufacturing, and IND filing. With strong expertise and capabilities to develop and manufacturing innovative biologics, HJB will continue to deliver high quality, reliable, and rapid service which empowering our global partners to accelerate their innovative treatment development.” said Dr. Jerry Yang, General Manager of HJB.
Kanova Biopharma was founded by a world-renowned immunologist in 2015. Based on its cutting-edge research in immunology, Kanova focuses on developing first-in-class therapeutic antibodies or innovative combo therapies to treat cancer and autoimmune diseases.
HJB employs an integrated leading technology platform capable of substantially accelerating R&D process and reducing cost for speedy commercialization. We offer our clients complete, flexible, and reliable development and manufacturing services for the entire lifecycle of their biologic’s product from research, preclinical, IND to all clinical phases and commercial production.